A B S T R A C T Healthy adult male volunteers were immunized with purified M protein from Group A streptococci, Type 1. The vaccine was administered subcutaneously as an aluminum hydroxide-precipitated antigen in three monthly doses. Control subjects received a placebo of the aluminum hydroxide adjuvant. To test the efficacy of the immunization, vaccinees and controls were challenged with a virulent strain of Type 1 streptococci applied to the pharynx. The immunization and challenge of the vaccinated and control subjects (19 men in each group) were carried out as a double blind experiment. All subjects were carefully screened by physical and laboratory examinations before and after the immunization and infectivity schedules. 30-50 days after the last injection, the vaccinees and control subjects were infected with the streptococci. Careful surveillance was maintained to evaluate the extent of acquired streptococcal infection. Throat cultures, leukocytes counts, temperatures, and physical signs and symptoms were monitored daily. All subjects received 1.2 million U of penicillin intramuscularly no later than 6 days after inoculation with the culture. Illness was judged by the appearance of exudative pharyngitis and cervical adenopathy accompanied by a positive throat culture. By these criteria, 9 of the 19 placebo controls,-and 1 of 19 vaccinees were ill. No residual illness or clinical complications was observed after the penicillin treatment. It is concluded that the alum-precipitated M protein vaccine afforded protection against an upper respiratory Type 1 streptococcal infection.
INTRODUCTION
Acquired immunity after a Group A streptococcal infection is type-specific, and is believed to result primarily from the induction of bactericidal (opsonic) antibodies. These antibodies are directed against the M antigens, the cell wall proteins responsible for the specificity of the 50 or more serotypes within Group A (1) . Methods for the purification of M proteins and the induction of active immunity have been studied in this laboratory for the past 7 yr (2) (3) (4) . Purified M protein vaccines were shown in experimental animals to be immunogenic in the absence of local or systemic reactions. These experiments led to cautious human clinical experimentation with M protein vaccines (5, 6) . To date, over 150 adults and 90 infants and children have been immunized with M protein vaccines of the more common sterotypes, 1, 3, 6, and 12. Generally, three doses of 50 ,g of M protein precipitated with alum sufficed to induce primary bactericidal antibodies in about 75% of young children. By selecting subjects without delayed cutaneous hypersensitivity to I-Ag intracutaneous doses of the soluble M protein, local and systemic reactions to the immunogenic vaccine have been largely avoided.
Long-term field trials with populations of children or young adults at risk in communities where streptococcal upper respiratory disease is prevalent will be the ultimate test of the efficacy of M protein vaccines. In the meantime, the protective capacity of a Type 1 M protein vaccine has been assessed by immunizing a limited number of adult volunteers and challenging them with live homologous streptococci. The details and outcome of these infectivity experiments are presented.' METHODS M protein vaccine and reagents. Purified M protein was prepared from cell walls of Group A streptococcus, strain CDC SS-496, Type 1. This organism was passed through mice three times to improve M protein production and virulence. Procedures for the purification and preparation of alum-precipitated M-1 protein (APM-1)2 and soluble M-1 protein have been described in detail (3, 4) . One dose of APM-1 consisted of 90 ,ug of purified M protein combined with 2.5 mg of aluminum hydroxide in 0. 5 Antibody assay. Serum from each subject was collected just before the vaccine or placebo inoculations and 30 days after the last dosage. Type-specific antibody was assayed by a microcomplement fixation assay (8) and the indirect bactericidal test (9) . In the indirect bactericidal assay, the number of colonies growing on a blood agar plate after incubation with human leucocytes and test serum were counted. The level of bactericidal antibodies was compared to normal rabbit serum. In scoring results, + equals a 0.5 log or greater diminution in the last two bacterial dilutions, + equals a 0.2-0.5 log diminution in the last two bacterial dilutions, and 0 equals no significant difference between colony counts after incubation in the test serum when compared to growth in normal rabbit serum. The percentage of complement fixed was determined in an assay system containing the test serum diluted 1: 100 and 0.1 ,&g of Type 1 2Abbreviations used in this paper: APM-1, alum-precipitated M-1 protein; PBS, phosphate-buffered solution; RLB, Ringer's lactate buffer. a general correlation between the presence of complementfixing M protein-specific antibodies and bactericidal activity (8) .
Culture and infectivity procedures. 18-h cultures of Group A Type 1 streptococci grown in Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) were washed in sterile 0.01 M phosphate-buffered saline (PBS) and resuspended in PBS to approximately 4 X 106 colony-forming U/ml, standardized by spectrophotometric measurement and subsequent colony counts on sheep blood agar plates. All subjects were infected between 30 and 50 days after the third dose of vaccine or placebo. A sterile cotton-tipped applicator was dipped once into this culture and the suspension was painted liberally over the pharyngeal and tonsillar areas. Throat cultures were obtained with cotton swabs wiped around the tonsillar ring and crisscrossed over the pharynx. The swabs were rolled at one edge of a sheep blood agar plate over a swath about 1 X 3 cm, and microorganisms in that area were streaked over the plate with a loop. During the course of immunization, throat cultures were obtained monthly from all subjects and no intercurrent Group A streptococci were observed.
Groups of 12-14 men, divided about equally between vaccinated and control subjects, were infected simultaneously. The first two groups of men were quartered individually under strict quarantine. Subsequently, groups of 10-12 subjects were maintained in an isolated 12-bed ward with about 4 ft of space between beds. The outcome of the experiment was independent of those two arrangements of quarters. Throat cultures were taken immediately before infection was initiated and daily thereafter. Temperatures were measured every 12 h and peripheral blood for leucocyte counts was obtained daily. Neither the subjects nor the personnel carrying out the laboratory and clinical evaluations were informed of the status of the volunteers as control subjects or vaccinees until the completion of the experiment.
After inoculation with the microorganisms, the men were observed for 6 days, during which time or immediately thereafter each man received an intramuscular injection of 1.2 million U of benzathine penicillin G and procaine penicillin G (Bicillin C-R, Wyeth Laboratories, Inc., Philadelphia, Pa.). All men whose throat cultures were positive during the 6-day observation period received a second dosage of penicillin 5 days after the first injection. Those who exhibited more severe signs and symptoms of infection (malaise with fever, chills, and physical prostration) received the penicillin therapy 18-24 h after the onset of symptoms. In these cases, the infection was treated 3-4 days after inoculation with the streptococci. The scoring system for the evaluation of illness is outlined in Table I. RESULTS Among the 19 vaccinees, postimmunization sera of 17 exhibited a significant (15% greater) increase in the type-specific complement-fixing antibody titer when compared to the preimmunization sera, and 5 of these immune sera contained opsonic antibody as well. None of the sera from the subjects who received placebo showed significant changes in the Type 1 antibody levels. These data are shown in Tables IIA and B. Before challenging the vaccinees and placebo control subjects, it was necessary to ensure that the Type 1 Table I . Five of the six men acquired positive throat cultures which persisted until the penicillin treatment on the 6th day after infection. Three of these five men showed obvious signs and symptoms of streptococcal infection as evidenced by pharyngeal erythema with exudate, enlarged, tender cervical lymph nodes, fever, leucocytosis, and moderate malaise. When we had thus established that the Type 1 streptococci were capable of inducing a clinical infection, the vaccinees and placebo control subjects were challenged in the same manner as the six untreated subjects of group I. 12-14 men at a time, equally distributed among groups II and III, were infected 30-50 day after receiving the last injection of M protein or placebo. Table IIA a The virulence of this Type 1 streptococcal strain had been previously established with four volunteers (medical students) about 10 mo before the present immunization trials began. These four. subjects developed upper respiratory infections similar in severity to subjects 3, 4, and 6 described in Table 2C . Because of the prolonged storage of the streptococcal cultures at -70'C and several transfers thereafter in laboratory media, it was deemed necessary to reconfirm the virulence of the strain as described above.
summarizes the result of the immunization and infectivity challenge of the 19 vaccinees. The degree of illness, defined by clinical signs and symptoms of an upper respiratory infection, was graded "none," "questionable," or "obvious." By the criteria of exudative pharyngitis and cervical adenopathy (i.e., enlarged, tender nodes) concomitant with the presence in the pharynx of Type 1 streptococci (confirmed by serotyping), 1 of the 19 vaccines had an obvious illness. Four others had mild signs and minimal symptoms and were classified as questionably ill. The remaining 14 men showed no significant signs or symptoms of infection and therefore were considered not ill. In contrast to the vaccinees, the rate of acquisition of infection was considerably higher among the subjects who had received placebo injections. In group III (Table 2B) Fig. 1 , all were negative 24 h after treatment, although in some of the other subjects, a few Group A Type 1 streptococci persisted for 24-48 h after antibiotic intervention. As previously mentioned, a second penicillin injection was administered to all infected subjects to ensure the complete elimination of the streptococci. Six vaccinees whose preliminary skin test resulted in a delayed cutaneous reaction of 0.3-0.6 cm exhibited a moderate swelling and tenderness at the sites of APM-1 injections, lasting 24-48 h. Four of these men had a transient fever of 1-20C for 12-24 h after the first two APM-1 injections. Complete laboratory and physical examinations of all subjects were carried out 3 wk after the penicillin treatment, and no residual illness resulted from this trial. indicate days on which subjects were infected with the culture and treated with p)enicilliln.
See Table II for explanation of the clinical evaluation. WBC, white blood cell count.
The results obtained from the three groups of men were analysed statistically by a system of hypergeometric distribution (10) . In evaluating the criteria of obvious illness, we included the requisites of exudative pharyngitis and/or tonsillitis, cervical adenopathy, and a positive throat culture. The volunteer without all of the above symptoms or signs was considered "not ill" for analytical calculations. In this dichotomous classification of the 44 subjects, 1 of 19 vaccinees was clinically ill, and 12 of the 25 controls were clinically ill. The probability (P) that the data could be the result of a chance distribution is less than 4 in 1000. If we consider only the 19 subjects who received APM-1 and the comparable 19 placebo controls, 1 of the vaccinees and 9 of the controls acquired a clinical infection; a statistical analysis of these results with 38 subjects yields a P < 0.01.
DISCUSSION
Our previous data on the use of a microcomplementfixing assay for type-specific antibody showed that with serotypes 3, 6, and 12, high titers of complement-fixing antibodies were generally indicative of bactericidal activity (8) . It was also observed that these complementfixing reactions were type-specific. We have no explanation as to why the Type 1 antibodies from the present vaccinees, although exhibiting relatively high titers in the microcomplement fixation reaction, were only bactericidal in about a third of these subjects. Approximately half of the vaccinees appeared to have no previous exposure to Type 1 streptococci, inasmuch as their antibody titers were not elevated until after the second or third dose of vaccine. There was no correlation between the appearance of rapid secondary response after the first dose of vaccine and the degree of illness resulting from the challenge.
The data indicate that although immunization with purified Type 1 M protein may present the acquisition of clinical illness in subjects challenged with homologous streptococci, the role of measurable bactericidal levels of antibody has not been clarified. (15) . This was only previously reported clinical trial in which the efficacy of a streptococcal vaccine was measured in terms of actual protection. Over 1,000 personnel were immunized with heatkilled or ultraviolet-inactivated Types 17 and 19 streptococci in three doses of approximately 10' cells/injection. The streptococcal attack rate among the immunized men, followed over a period of months, was not diminished when compared to unimmunized controls. No attempts were made to determine the antibody responses to the vaccines, and it may be surmised that the antigenic dose was not adequate to afford type-specific protection.
Massell, Michaels, Amezcua, and Siner, and Massell, Honikman, and Amezcua (16, 17) reported a streptococcal immunization study in which children, siblings of rheumatic fever patient, were immunized with as many as 18 weekly doses of partially purified M proteins. They succeeded in inducing type-specific antibodies in some of these children. However, among the vaccinees, two and possibly three cases of rheumatic fever developed in subsequent months because of streptococcal infections by heterologous serotypes. The authors stated that these cases of rheumatic fever could have developed as a result of "sensitization" to the vaccine material, allowing for greater susceptibility to the nonsuppurative complications during later exposure to Group A streptococci. It should be noted that in these experiments, Massell and colleagues employed an M antigen which, from a description of their methodology, could only be described as partially purified. Their dosages were approximately 100 times those used by Fox, Pachman, Wittner, and Dorfman (6) , who induced bactericidal antibodies in children with purified M proteins.
It is well established that group A streptococci share antigens in common with mammalian heart tissues. This was first demonstrated by Kaplan and Meyeserian, and Kaplan and Svec, who observed that cell wall antigens chemically or physically associated with M protein fractions cross-reacted with human myofibers (18, 19) . Several reviews summarizing research on the autoimmune hypothesis of rheumatic fever have been published (20, 21) 
